Eli Lilly and Company has stopped a Phase 2 study of a beta secretase inhibitor being investigated in Alzheimer’s disease as a result of abnormal liver tests in patients. The decision doesn’t affect other compounds in development, the company said. ---Subscribe to MedNous to access this article--- Clinical Research Company News
